Leap Therapeutics To Collaborate With Merck, Pfizer To Evaluate TRX518

Leap Therapeutics To Collaborate With Merck, Pfizer To Evaluate TRX518

Source: 
Business Insider
snippet: 

Leap Therapeutics, Inc. (LPTX) announced a collaboration agreement with Merck KGaA, and Pfizer to evaluate Leap's GITR agonist, TRX518, in combination with avelumab, a human anti-PD-L1 IgG1 monoclonal antibody, and chemotherapy.